title: [Vitamin D3 availability and functional activity of peripheral blood phagocytes in experimental type 1 diabetes].
abstract: The study was devoted to identifying the relation between vitamin D3 availability (assessed by the level of circulatory 25OHD3), content of vitamin D3 25-hydroxylase isozymes CYP27A1 and CYP2R1 in hepatic tissue and functional activity of peripheral blood phagocytes in mice with experimental type 1 diabetes. It has been shown that diabetes is accompanied by the development of vitamin D3-deficiency which is characterized by decreased 25OHD3 content in blood serum and determined by changes in tissue expression of the major isoforms of vitamin D3 25-hydroxylase. The level of hepatic CYP27A1 was revealed to be markedly reduced with a concurrent significant augmentation of CYP2R1. Cholecalciferol administration resulted in normalization of tissue levels of both isoforms of vitamin D3 25-hydroxylase and blood serum 25OHD3 content. Diabetes-associated vitamin D3 deficiency correlated with a decrease in phagocytic activity of granulocytes and monocytes, and their ability to produce antibacterial biooxidants such as reactive oxygen and nitrogen forms. Vitamin D3 efficacy to attenuate these abnormalities of immune function was established, indicating an important immunoregulatory role of cholecalciferol in the phagocytic mechanism of antigens elimination implemented by granulocytes and monocytes.
authors.forename: D O
authors.initials: DO
authors.lastname: Labudzyns'kyĭ
authors.forename: I O
authors.initials: IO
authors.lastname: Shymans'kyĭ
authors.forename: V M
authors.initials: VM
authors.lastname: Riasnyĭ
authors.forename: M M
authors.initials: MM
authors.lastname: Velykyĭ
mesh_terms: D000818:Animals; D002762:Cholecalciferol / Q000008:administration & dosage / Q000097:blood*; D053493:Cholestanetriol 26-Monooxygenase / Q000235:genetics / Q000378:metabolism*; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000188:drug therapy / Q000201:enzymology / Q000276:immunology*; D004926:Escherichia coli / Q000276:immunology; D015870:Gene Expression; D006098:Granulocytes / Q000187:drug effects / Q000276:immunology*; D008099:Liver / Q000187:drug effects / Q000201:enzymology / Q000276:immunology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009000:Monocytes / Q000187:drug effects / Q000276:immunology*; D010587:Phagocytosis / Q000187:drug effects; D026361:Reactive Nitrogen Species / Q000276:immunology / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000276:immunology / Q000378:metabolism; D013311:Streptozocin; D014808:Vitamin D Deficiency / Q000150:complications / Q000188:drug therapy / Q000201:enzymology / Q000276:immunology*
chemical_list: D026361:Reactive Nitrogen Species; D017382:Reactive Oxygen Species; D002762:Cholecalciferol; D013311:Streptozocin; C569548:Cyp2r1 protein, mouse; D053493:Cholestanetriol 26-Monooxygenase; C506832:Cyp27a1 protein, mouse